AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2716477
Drug: Bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5 mg/day) with naloxone (1.6 mg/h for 4 h)
Trial: 2716477
Drug: Bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5 mg/day) with saline
Trial: 1017879
Drug: +Pat. (antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +Pat. (antibiotic prophylaxis with penicillins or cephalosporins)
Trial: 1017879
Drug: ‐Pat. (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ‐Pat. (no antibiotic treatment)
Trial: 31326458
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus fixed-dose combination glimepiride 1 mg and metformin 500 mg twice daily (G/M group)
Trial: 31326458
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus glimepiride 4 mg once daily (G group)
Trial: 26975399
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac 0.1% (four times daily for 6 weeks post-surgery)
Trial: 26975399
Drug: Conventional postoperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional postoperative care with steroid drop
Trial: 26088896
Drug: Perampanel (DB-PER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (DB-PER 12 mg)
Trial: 23510102
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing counseling with 21‐mg nicotine patch
Trial: 23510102
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (one session of brief advice to quit smoking) with 21‐mg nicotine patch
Trial: 21864166
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg daily for 1 year)
Trial: 19825960
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events after treatment
Trial: 11737375
Drug: Saquinavir hard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir hard gel
Trial: 9161875
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment at 0.1 IU/kg/day
Trial: 9161875
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment at 0.2 IU/kg/day
Trial: 9161875
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment at 0.3 IU/kg/day
Trial: 8260285
Drug: Remotely controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remotely controlled mechanical pump for contrast injection
Trial: 8260285
Drug: Hand injection
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hand injection of contrast
Trial: 12942029
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of spironolactone plus standard therapy
Trial: 12942029
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy only (Control group)
Trial: 1342896
Drug: Terfenadine 120
RxNorm normalized name: terfenadine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 120 mg once daily for 7 days
Trial: 1342896
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg once daily for 7 days
Trial: 3908127
Drug: DDP (cis‐diammine‐dichloroplatinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDP (cis‐diammine‐dichloroplatinum II) 50 mg/m2 in Group A with heavy osmotic hydration
Trial: 3908127
Drug: DDP (cis‐diammine‐dichloroplatinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDP (cis‐diammine‐dichloroplatinum II) 50 mg/m2 in Group B over 3 consecutive days
Trial: 26385228
Drug: CoQ10 supplementation
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 supplementation (100 mg daily for 8 weeks)
Trial: 25297013
Drug: ALD403 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALD403 1000 mg
Trial: 18589423
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg daily for 15 days
Trial: 7740123
Drug: Electrodermal conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrodermal conditioning with intermixed pre-training and compound training trials; specific dosage and duration not mentioned.
Trial: 7740123
Drug: Overshadowing control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overshadowing control group; specific dosage and duration not mentioned.
Trial: 6290754
Drug: Etoposide maintenance
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide maintenance therapy
Trial: 6290754
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further maintenance therapy
Trial: 6290754
Drug: Chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen (ACO)
Trial: 30897134
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy and pulmonary rehabilitation
Trial: 15363007
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (800 micro g budesonide) for 12 weeks
Trial: 11822764
Drug: high-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose therapy
Trial: 9516059
Drug: Low-dose ramipril
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ramipril (1.25 mg) over 4 weeks
Trial: 8071053
Drug: Iopromide (370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopromide (370 mg I/mL)
Trial: 8071053
Drug: Iopamidol (370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamidol (370 mg I/mL)
Trial: 8071053
Drug: Iohexol (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol (350 mg I/mL)
Trial: 3127845
Drug: Amitriptyline at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline at low plasma drug levels
Trial: 3127845
Drug: Amitriptyline at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline at medium plasma drug levels
Trial: 3127845
Drug: Amitriptyline at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline at high plasma drug levels
Trial: 3127845
Drug: Amitriptyline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline treatment in patients aged 25 to 65 years
Trial: 3127845
Drug: Amitriptyline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline treatment in patients aged 65 to 80 years
Trial: 29610026
Drug: Accelerated corneal
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated corneal crosslinking (CXL) using higher fluence (7.2 J/cm2) and treatment time (4 minutes)
Trial: 27716157
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% (6.7 ml)
Trial: 27716157
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% (10 ml)
Trial: 27716157
Drug: Ropivacaine 0.25%
RxNorm normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.25% (20 ml)
Trial: 20575271
Drug: Hib vaccine
RxNorm normalized name: ActHIB vaccine 0.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib vaccine
Trial: 15966757
Drug: Modafinil 400
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 400 mg/day
Trial: 17646493
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 1.5 microg/kg
Trial: 14692723
Drug: Kava special
RxNorm normalized name: KAVA
DrugBank: Kava (DB01322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kava special extract WS 1490 (150 mg/d, 3 x 1 capsule of 50 mg/d)
Trial: 18466078
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of hyperthyroidism
Trial: 24200100
Drug: Integrative Treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative Treatment (IT)
Trial: 12927999
Drug: Newer cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer cytotoxic agents (gemcitabine, PEG-liposomal doxorubicin, topotecan) in combination with platinum-based therapy
Trial: 12927999
Drug: Standard platinum/taxane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard platinum/taxane therapy (carboplatin and paclitaxel)
Trial: 1622957
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 5% eutectic mixture of lignocaine and prilocaine (EMLA) (n = 15)
Trial: 6381775
Drug: Moxalactam and
RxNorm normalized name: moxalactam
DrugBank: Moxalactam (hydrolyzed) (DB04740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam and ampicillin sodium therapy
Trial: 6381775
Drug: Amikacin sulfate
RxNorm normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin sulfate and ampicillin therapy
Trial: 26686567
Drug: Lomitapide (10-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomitapide (10-60 mg)
Trial: 24794720
Drug: 0.5-mg nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-mg nitroglycerin gel (1 mL) applied vaginally 30 min prior to IUD placement
Trial: 24794720
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo gel applied vaginally 30 min prior to IUD placement
Trial: 20350942
Drug: vicriviroc-ritonavir (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vicriviroc-ritonavir (30 and 100 mg)
Trial: 20350942
Drug: vicriviroc-ritonavir (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vicriviroc-ritonavir (150 and 100 mg)
Trial: 23155151
Drug: ritonavir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ritonavir (100 mg)
Trial: 20350942
Drug: vicriviroc (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vicriviroc (200, 250, or 300 mg)
Trial: 20350942
Drug: vicriviroc (150,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vicriviroc (150, 200, or 250 mg)
Trial: 16227990
Drug: Combination immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination immunotherapy consisting of a single early post-transplant infusion of in vivo vaccine-primed and ex vivo costimulated autologous T cells followed by post-transplant booster immunizations
Trial: 16227990
Drug: Early T-cell
RxNorm normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early T-cell infusions
Trial: 16227990
Drug: Combination vaccine
RxNorm normalized name: Hepatitis vaccine combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination vaccine therapy and adoptive T-cell transfer
Trial: 9456253
Drug: Indinavir in
RxNorm normalized name: Product containing indinavir in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir in combination with nucleoside analogue reverse transcriptase inhibitors
Trial: 7610506
Drug: LHRH analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH analogues treatment
Trial: 2540581
Drug: Lonidamine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lonidamine (up to 1050 mg/day)
Trial: 2540581
Drug: MVP (mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVP (mitomycin C 10 mg/m2, vinblastine 5 mg/m2, cisplatin 100 mg/m2)
Trial: 779590
Drug: Alprenolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprenolol (400 mg daily, increased to 533 mg)
Trial: 779590
Drug: Pindolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (20 mg daily, increased to 25 mg)
Trial: 21671884
Drug: Tipranavir/ritonavir (TPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipranavir/ritonavir (TPV/r) administered twice daily for 10 days
Trial: 21671884
Drug: Darunavir/ritonavir (DRV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir (DRV/r) administered twice daily for 10 days
Trial: 21671884
Drug: Ritonavir (RTV)
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir (RTV) administered alone for 10 days
Trial: 2010565
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg single dose)
Trial: 6859836
Drug: Amantadine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (100 or 200 mg daily for 5 days)
Trial: 6859836
Drug: Aspirin (3.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3.25 g daily for 5 days)
Trial: 26432693
Drug: Evidence-based depression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based depression care management for 2 years, including psychotherapy and medication management
Trial: 22708640
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (50-100 mg daily)
Trial: 18051491
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of paracetamol as a single intravenous preemptive dose
Trial: 7759701
Drug: Metoprolol (Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (Controlled Release, 200 mg once daily)
Trial: 7759701
Drug: Nifedipine (Retard,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (Retard, 20 mg twice daily)
Trial: 29486881
Drug: Topical regenerative
RxNorm normalized name: Regener-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical regenerative agent
Trial: 26921460
Drug: Adjunctive antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive antimicrobial photodynamic therapy (aPDT) with indocyanine green (ICG) + SRP
Trial: 11369986
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (1000 ml)
Trial: 25568553
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride 0.9% (1000 ml)
Trial: 22233204
Drug: Tofacitinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (30 mg twice daily for 6 days)
Trial: 22233204
Drug: Midazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (2 mg single dose)
Trial: 20434823
Drug: BIG Bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIG Bone Injection Gun
Trial: 16120067
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg twice daily for 5 days)
Trial: 16120067
Drug: Omeprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (30 mg once daily for 6 days)
Trial: 12131606
Drug: Infliximab 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab 5, 10, or 20 mg/kg
Trial: 7779149
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tenoxicam (2 x 20 mg on days 1 and 2)
Trial: 87082
Drug: Oral retinoid
RxNorm normalized name: tretinoin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral retinoid (Ro 10‐9359) and UVB radiation (Selective Ultraviolet Phototherapy=SUP)
Trial: 87082
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy only (control group)
Trial: 23333292
Drug: buprenorphine/naloxone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buprenorphine/naloxone treatment for 12 weeks
Trial: 19435390
Drug: Nonpharmacologic methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic methods or other medications
Trial: 14722734
Drug: ZD9331 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD9331 in combination with cisplatin (100 mg/m2 and 50 mg/m2)
Trial: 14722734
Drug: ZD9331 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD9331 in combination with cisplatin (130 mg/m2 and 50 mg/m2)
Trial: 14722734
Drug: ZD9331 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD9331 in combination with cisplatin (130 mg/m2 and 75 mg/m2)
Trial: 14722734
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (ZD9331 and cisplatin)
Trial: 2893877
Drug: Prophylactic cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cranial irradiation at a total dose over 2000 cGy (group I)
Trial: 2893877
Drug: Prophylactic cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cranial irradiation at a total dose of 1800 cGy (group II)
Trial: 23240729
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text messages (TM) for 12 weeks
Trial: 17298190
Drug: Multifactorial educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactorial educational intervention by a pharmacist including disease information, drug therapy, diet education, and active telephone follow-up.
Trial: 9220319
Drug: Prophylactic low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prophylactic low-dose dopamine (2 mg/kg/min) administered 1 hour before IL-2 and discontinued 6-12 hours after maximum IL-2 doses.
Trial: 9220319
Drug: Prophylactic low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prophylactic low-dose dopamine (2 mg/kg/min).
Trial: 7698967
Drug: Saphenous vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saphenous vein patch
Trial: 7698967
Drug: PTFE patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTFE patch
Trial: 2439856
Drug: Empirically devised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirically devised regimen of forceful spinal manipulation and injections of a dextrose‐glycerine‐phenol ('proliferant') solution
Trial: 2439856
Drug: Parallel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parallel treatment with less extensive initial local anaesthesia and manipulation, and saline substitution for proliferant
Trial: 27582635
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group B)
Trial: 25268778
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive containing 20 mcg of ethinyl estradiol and 3 mg of drospirenone
Trial: 18809731
Drug: Duloxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30 mg b.i.d.)
Trial: 18809731
Drug: Desvenlafaxine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (100 mg/day)
Trial: 9935203
Drug: MAGE-3.A1 peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE-3.A1 peptide (3 subcutaneous injections at monthly intervals)
Trial: 2719466
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg every 12 h for 3 days)
Trial: 2719466
Drug: Aminophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (6 mg/kg by 30-min intravenous infusion)
Trial: 31127607
Drug: Individualized FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized FSH dose (100 IU/d for predicted hyper responders)
Trial: 31127607
Drug: Standard FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard FSH dose (150 IU/d)
Trial: 31127607
Drug: Individualized FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized FSH dose (450, 225, or 100 IU/d based on AFC)
Trial: 28778281
Drug: High progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High progesterone levels on the day of hCG administration
Trial: 28778281
Drug: Normal progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Normal progesterone levels on the day of hCG administration
Trial: 25662406
Drug: KRM-20 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRM-20 (20 mg)
Trial: 25662406
Drug: KRM-20 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRM-20 (6 mg)
Trial: 25662406
Drug: KRM-20 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRM-20 (60 mg)
Trial: 25662406
Drug: KRM-20 (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRM-20 (16 mg)
Trial: 25662406
Drug: KRM-20 (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRM-20 (1.6 mg)
Trial: 17572615
Drug: Conventional corpectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional corpectomy (CC)
Trial: 17572615
Drug: Both CPW
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both CPW and CC
Trial: 9885179
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg acetylsalicylic acid (ASA)